Erectile dysfunction (ED) is a widely occurring benign disorder that affects men of all ages. The prevalence and severity of ED increases with age and results in considerable distress and impact on quality of life for those who suffer from it. As ED is associated with a wide variety of underlying conditions and co-morbidities there is a requirement for diversity of treatment options beyond those currently available. In the management of the ED patient both primary care and specialist physicians have an important role to play. This article reports on a stepwise approach for the diagnosis and treatment of ED, with an emphasis on a 'shared care' approach. The suitability of apomorphine SL (Uprima 1 ) for the front line management of the ED patient is described.
Introduction
Our understanding of, and attitude to, male sexual health, and in particular, erectile function and dysfunction, is dynamic and has been continuously evolving. 1 -6 As recently as 25 y ago, this field was considered to be the exclusive domain of psychologists and=or endocrinologists. The advent of penile prosthesis insertion in 1973 and other, non-surgical, therapies such as vacuum constriction devices and local self-injection of therapeutants in the 1980s brought the urologist to the forefront of clinical practice. This speciality has contributed greatly to current understanding of the physiology of the erectile process, the pathophysiology of erectile dysfunction (ED) and diagnostic and therapeutic options in patient management. Not surprisingly, from the therapeutic perspective alone, there has been, and continues to be, considerable improvement in the availability of user-friendly, reliable and dependable interventions in the area of male sexual health. 1 -6 Despite the prevalence of ED, 6 up to the late 1990s fewer than one in 10 men sought treatment for this disorder and even within this sub-population, a high treatment drop-out rate was routinely observed. 1 -5 Reasons advanced include the fact that treatment has been relatively invasive=intrusive in nature or artificial, has associated risks, may be irreversible and is expensive. On this basis, it was anticipated that the general availability of the first effective oral therapeutant, sildenafil, 7 for the management of ED would have a considerable and far-reaching impact on the management of male sexual health issues. Certainly, there has been a major change in medical focus; primary care physicians have increasingly become the front line in the management of patients complaining of sexual disorders. It is pertinent to note, however, that even with the arrival of sildenafil the majority of men suffering from ED still do not present to discuss the condition with their physician.
The advent of more widespread disease awareness and the availability of orally active agents have resulted in the requirement for accepted treatment algorithms to be used specifically as the potential basis for patient management in the community setting. The objective is to facilitate dialogue between physicians, patients and, increasingly, the initial health care provider in issues relating to male sexual health. One example, based on that developed by the International Consultation on erectile dysfunction, 8 is shown in Figure 1 .
Penile erection is a complex series of integrated vascular events resulting in accumulation of blood under pressure and end-organ rigidity. Although it relies on the co-ordination of various neural and humoral events at several levels of the neuroaxis, there is an absolute requirement for central neural input to provide normal function. Any imbalance can result in ED. Traditionally, drugs have been developed to act as peripheral vasodilators. An alternative approach involves the production of an erectogenic action within the central nervous system (CNS). Apomorphine SL is the first example of a drug acting exclusively within the CNS to re-dress any imbalance in central processing and thereby providing benefit across a wide range of aetiologies. 8 
Definition of erectile dysfunction
The consensus panel definition of ED (formerly termed impotence) was as follows: ED is the consistent or recurrent inability of a man to attain and= or maintain an erection sufficient for satisfactory sexual performance.
Classification of erectile dysfunction
ED may be classified based on severity, aetiology or onset.
When classified on a severity basis, ED can be stratified as mild, moderate or severe, depending on the ability to attain and=or maintain an erection with either intermittent (mild), infrequent (moderate) or absent (severe) satisfactory sexual performance.
Although the conditions frequently coexist, on the basis of aetiology, ED is defined as either Using onset as the criterion, ED is classified as either primary or secondary. The former, which is uncommon, is that which occurs in men who have never had the ability to attain and=or maintain an erection. The potential causes include deep-seated psychological conflicts or perineal=pelvic trauma. Secondary ED is that which is acquired following a period of satisfactory sexual performance and is the most common.
It is also important to remember that ED patients present with many other co-morbidities, 9 ( Figure 2 ), particularly diabetes and hypertension, both of which may be controlled or un-controlled. These can be important factors in the selection of the most appropriate treatment.
Diagnosis and assessment of erectile dysfunction
As with any medical condition, the ideal foundation for the management of ED is a careful clinical evaluation. As a minimum, thorough medical and psychological histories, physical examination and focused laboratory testing are recommended. More specialised diagnostic tests (eg nocturnal penile tumescence and rigidity or penile vascular studies) are available and may be justifiable in individual patients. However, it should be stressed that the cornerstone of clinical assessment remains a detailed sexual, medical and psychological history. This accomplishes several goals, including characterisation of the problem and identification on patients and partner needs and priorities, as well as fostering a good relationship between physician and patient. Although this is not always possible on the first visit, every effort should be made to involve the patients' partner as early as possible.
The first phase of the evaluation is to determine whether the patient meets the consensus definition of ED ie has a consistent or recurrent inability to attain and=or maintain an erection sufficient for sexual performance. Subsequently other issues can be tackled. These relate to whether intervention is 
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A von Keitz warranted and whether ED is the primary complaint or is associated with or misinterpreted as, another sexual dysfunction such as premature ejaculation or hypoactive desire. The next phase of the evaluation, following problem identification, is the obtaining of a comprehensive sexual, medical and psychological history. In addition to the usual concerns in medical history taking, clinicians should pay special attention to the sensitivity of the topic, as well as looking at this as an opportunity to initiate patient and partner education and communication.
Within the scope and capability of the primary care physician is arrangement for supportive laboratory evaluations. Obviously, however, there can be issues relating to cost containment within certain health care environments that can render such testing impracticable. Of particular importance may be an evaluation of the hypothalmic -pituitary -gondal axis via assessment of serum testosterone and prolactin levels. Abnormalities of either may correlate with diminished libido and reduced sex glandular mass. Also of merit are evaluations of serum lipids, which can be predictive of vasculogenic (atherosclerosis-based) ED, assessments relating to diabetic control and other evaluations including prostate-specific antigen.
Specialised diagnostic testing may be indicated in several circumstances, as follows: (a) if the initial laboratory assessment reveals abnormalities potentially warranting further evaluation to enable a more precise diagnosis; (b) if the selected treatment option required more specialised diagnostic assessment (eg penile ultrasound and angiography prior to penile revascularisation) prior to decision-making; (c) if the patient would prefer a more comprehensive evaluation and understanding prior to election of a treatment option; (d) for medicolegal reasons.
Specialised diagnostic tests for ED include a wide range of vascular, neurological and endocrinological studies. Although specialists, often in gaining insight into the underlying pathophysiology, may routinely use these tests, their use should be reserved for selected cases in the primary setting. Although useful knowledge can be gained, their utility may be limited by expense and associated risks. Historically, particularly in the USA, nocturnal penile tumescence and rigidity (NPTR) testing has been relatively widely used and was used in the discrimination of organic and psychogenic dysfunction. NPTR studies can be conducted in a sleeplaboratory or, more commonly, in an ambulatory setting. Overall, however, NPTR is no longer widely used during the initial diagnostic work up. Also of interest, but only really feasible in the office evaluation, is the use of intracavernosal injection of pharmacological agents (such as prostaglandin E1 (PGE1) or 'trimix') to determine functional assessment of penile arterial inflow and veno-occlusive integrity. There is an increasing tendency, however, to use oral sildenafil in this form of 'diagnosis'.
It has become obvious with the advent of effective oral agents, that an increasing amount of diagnostic evaluation takes place in the primary care environment. However, more complex evaluation particularly of poor or non-responders to therapeutic agents, will be necessary. It is almost certain that this will involve dialogue with, and referral to, a specialist, to ensure the ultimate in patient care management. In many cases, subsequent to referral to a specialist the responsibility for patient management will be returned to the primary care physician and essentially the patient will be subject to 'shared care'. The concept of shared care is widely and successfully employed across Europe in the management of prostatic disease.
Indications for referral
Operating within the context of a shared care health care policy, potentially most patients with ED could be managed within the primary care environment should such an infrastructure exist. However the availability and access to primary care physicians who have an interest in and are prepared to treat sexual health will be highly country dependent. Even assuming that most cases can be managed by primary care physicians, in specific circumstances, referral to a specialist will be required for additional diagnostic testing, patient management or indeed surgery. The need of referral or consultation may arise at any time from initial evaluation, ie prior to or during the course of treatment or follow-up. When referring patients care should be taken to ensure that patients are fully informed about the reasons for referral, the evaluations to be undertaken and the potential outcomes. Equally, after referral, results should be carefully reviewed with the patient.
Specific indications for specialists referral include the following:
1. In situations where laboratory evaluations are ambiguous or to identify the need for more comprehensive evaluation; 2. When there is primary ED, eg in young patients with a pelvic=perineal trauma; 3. In patients with significant penile curvature (eg Peyronie's disease and congenital deformity); 4. In situations of a request from a patient or a medico-legal requirement for further evaluation.
Specialist referrals will be to urologists, psychiatrists, endocrinologists, sex therapists, or vascularreconstructive or neurosurgeons, as appropriate.
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Management of the ED patient
Patient management options can be subdivided into lifestyle modification and treatment interventions. The latter, in turn, can be considered as first-line (primary), second-line (secondary) or third-line (tertiary) options. The treatment algorithm ( Figure  1 ) is based on a stepwise approach to disease management. Treatment would normally follow the above order.
Epidemiological analysis shows that a number of risk factors and lifestyle issues can contribute to the occurrence of ED. In keeping with a stepwise approach, risk-factor modification usually represents the least invasive and therefore the first approach. In the present era of cost containment, although quantification or risk-factor modification on ED is lacking, good clinical practice mandates that this is an initial focus. This may often be attempted, however, in parallel with a more direct (ie therapeutic) intervention. By analogy to the general systemic circulation, as the penis is a modified vascular bed, modification of cardiovascular risk factors would certainly represent an obvious starting point; these include hyperlipidaemia and hypertension. Environmental factors such as cigarette smoking and alcohol abuse may also contribute to cardiovascular disease and=or ED. Equally, modification of several other behaviours relating to inter-partner relationships and sexual behaviours and conflicts may be of benefit. Finally, many patients presenting with ED have a history of prescription and non-prescription drug use and abuse. On this basis, in many instances ED may have an iatrogenic origin. 10 One viable treatment option could involve withdrawal or replacement of existing agents. Obviously however, caution should be exercised to ensure that primary therapeutic activity eg control of hypertension or antidepressant activity is not compromised.
The next level of patient management would involve therapeutic, device or surgical intervention. Three levels of treatment intervention are apparent when stratified on the clinical criteria of: ease of administration; reversibility; invasiveness and cost. Efficacy is an underlying assumption for all interventions designated as first-line (primary), secondline (secondary) and third-line (tertiary).
First-line interventions are primarily oral erectogenic agents 7, 11 vacuum erection devices and psychosexual therapy. In addition to meeting the above criteria, the primary interventions all have relatively low risk profiles, which make them particularly important considering the heterogeneity of patients in the primary care setting. Within the primary category, the selection of individual agents or strategies will be dependent on patient profile and need, medical indications and contraindications, as well as cost and reimbursement. In specific instances (eg documented endocrine abnormality), hormone replacement therapy may also be considered as first-line therapy.
To the list of options for first-line therapy, apomorphine SL (Uprima 1 ) can now be added. Apomorphine SL has been shown to have a rapid onset of action (71% of erections are within 20 min) and a consistent and predictable response ( 90% of attempts were successful in long term studies of responders) that is independent of the baseline severity (mild, moderate or severe (Figure 3) ), the underlying aetiology or the presence of significant co-morbidities (Figure 4) . 12, 13 The side effect profile of Uprima 1 is likewise benign ( Table 1 ). This overall benefit-risk profile, coupled to the relatively rapid onset of action and the 'natural' erections achieved 12, 13 could translate into a considerable improvement in patient satisfaction compared to existing therapies. Overall therefore, Uprima 1 should represent a welcome addition to the therapeutic armamentarium available to the physicians and patient, alike. Management of ED in the community A von Keitz Second-line treatment interventions are selected on the basis of (a) failure or insufficient response or adverse effects associated with one or more of the above primary therapies, and (b) patient preference. These interventions are based on local (intraurethral or intracavernosal) delivery of pharmacological agents. In general, vasoactive agents and other agents such as PGE1 are employed as monotherapy, in combination or as drug cocktails. Although widely used, drug administration by these routes is subject to more variable efficacy than observed via more conventional routes, high patient discontinuation rates, side effects (local and systemic), concerns regarding long-term safety and trauma, and a moderately high cost.
Although historically the first option, surgical implantation of semi-rigid or inflatable penile prostheses is now considered tertiary intervention. The surgery is highly invasive and is associated with potential complications; it is essentially irreversible and as such is now reserved for select cases of severe, treatment-refractory ED. However, despite these concerns and the high cost, penile prostheses have been associated with a high rate of patient satisfaction in several studies.
In summary, there are several advantages and disadvantages associated with all current treatment of ED. Available treatment options vary widely in the degree of invasiveness, level of efficacy and side effects, patient acceptability and compliance, and cost. Paramount in the selection of treatment modality is patient and partner preference. This represents a major paradigm shift from the traditional physician-directed strategy employed in most other diseases. Ultimately, the long-term success of any therapy is intimately associated with appropriate patient use and compliance and requires sustained monitoring and follow-up by the physician.
Sexual function consists of a complex series of interacting behavioural, emotional and physiological processes and ED can arise from minor perturbations at several loci. The response to a drug is likely to be situational and highly dependent on the nature of the imbalance. Thus the patient perception of clinical efficacy is likely to be highly dependent on the sexual milieu of the patient. This along with patient preferences and drug profile should be the major determinant in the choice of agent.
Given this need for customisation of therapy to individual patient needs the clinical profile of apomorphine SL (Figures 3 and 4) would suggest that it will be an invaluable addition to existing treatment options.
Conclusions and prospects
The advent of proven effective orally active agents has had a major impact on the treatment of ED. However, in this post sildenafil era, still only a minority of patients present. Of these, the primary care physician treats the majority. In an attempt to legislate for increased demand for diagnosis and management of ED in the primary care setting it is essential that urologists provide the lead in developing treatment algorithms and the development of 'shared care' approaches to patient management. The field of male sexual health is, however, still dynamic and continuously undergoing change. Uprima 1 will make a welcome addition as a safe and effective therapy for ED management within all health care environments. 
